Home › Funds › Second Line Capital, LLC › OCUL

Second Line Capital, LLC position in OCUL

OCULAR THERAPEUTIX INC · Health Care

Second Line Capital, LLC reported holding 656,848 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q3 2026 13F filing — a position valued at US$5.0M, representing 0.88% of its reported portfolio and ranking #22 among its reported holdings. Second Line Capital, LLC has disclosed OCUL holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)656.85K sh
Reported value held$5.04M
Portfolio Weight0.88%
First reportedQ2 2024
Last changeAdd
Updated2026-11-10

Last updated: 2026-11-10 · Source: SEC EDGAR Form 13F-HR

How Second Line Capital, LLC's OCUL position evolved

Second Line Capital, LLC first disclosed a stake in OCUL in Q2 2024 at 262,810 shares (US$1.8M). The position peaked in Q2 2026 at 638,640 shares, worth US$6.3M. Across 10 filings, Second Line Capital, LLC increased the stake 8 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 656,848 shares valued at US$5.0M — an increase of 18,208 shares quarter over quarter.. Notable position changes include a 29% increase in Q4 2024 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 262.81K $1.80M New
Q3 2024 262.81K $2.29M Hold
Q4 2024 340.10K $2.90M Add
Q1 2025 346.10K $2.54M Add
Q2 2025 385.47K $3.58M Add
Q3 2025 402.47K $4.70M Add
Q4 2025 500.75K $6.08M Add
Q1 2026 528.29K $4.95M Add
Q2 2026 638.64K $6.27M Add
Q3 2026 656.85K $5.04M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About OCUL and 13F data

OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 43 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$193.3M), Avoro Capital Advisors LLC (US$123.1M), SUMMER ROAD LLC (US$119.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding OCUL

All OCUL fund holders →

FAQ

How long has Second Line Capital, LLC held OCUL?

Second Line Capital, LLC has disclosed OCUL holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is Second Line Capital, LLC's current position in OCUL?

As of Q3 2026, Second Line Capital, LLC holds 656.85K shares of OCUL (OCULAR THERAPEUTIX INC), valued at $5.04M, representing 0.88% of its reported portfolio and ranking #22.

Has Second Line Capital, LLC been buying or selling OCUL?

In the latest 13F filing (Q3 2026), Second Line Capital, LLC increased its position in OCUL. The position peaked in Q2 2026 at 638.64K shares.

Which other funds hold OCUL?

Other major institutional holders of OCUL include Deep Track Capital, LP, Avoro Capital Advisors LLC, SUMMER ROAD LLC, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.